While numerous pre-clinical studies have supported the benefit of hormone therapy in reducing the incidence of age-associated brain dysfunction (including reducing the risk for Alzheimer's disease (AD)), results from the Women's Health Initiative (WHl) have suggested the contrary and left the field unsettled as to the future of hormone therapy. However, important caveats of the WHl include the possibility that the duration of postmenopausal hormone deprivation diminish the protective brain response to steroid hormones, suggesting the concept of a finite therapeutic window of opportunity for estrogens and/or progestins. During the first period (4 years) of funding, this Program Project sought to identify and characterize new and alternative mechanistic targets through which estrogens and progestins affect the brain. The intent was to achieve a broader perspective on the neurobiology of steroid hormones and a better conceptual understanding of how these hormones protect the brain from insults relevant to age and age-associated diseases such as AD. These studies were successful and showed that membrane progesterone receptors, a mitochondria localized estrogen receptor, and intracellular Ca2+ channels (IP3 receptors and Ryanodine receptors) are key targets for estrogens and/or progesterone (P4), particularly within the context of brain protection. In this competitive renewal, we propose to apply our findings from the first period of funding to test our overall hypothesis that the expression and/or function of these novel targets dictate the sensitivity of the brain to the protective effects of estrogens and P4, and therefore define the """"""""critical window"""""""" of therapeutic opportunity. Our team of researchers will address the overall hypothesis by integrating their respective Project-specific analyses (which themselves have common themes, such as hormone-induced cell signaling) into a common animal model (the OVXed rat, enabled by Core B), and then translating the results into human samples (brain samples from surgically menopausal women and their respective controls - enabled by Core A). Successful completion of the studies proposed will serve as the framework for defining strategies to expand the therapeutic window. That is, interventions that help maintain the expression and/or function of progesterone receptors, mitochondrial ER? and intracellular calcium channels may help maintain the brain's capacity to respond to estrogen and P4. Together, these strategies will lead to the development of safer and more effective therapeutic strategies for treating the menopause and reducing the risk for various brain disorders (including AD) whose risk increases during the post'-menopausal period.
With increasing numbers of women reaching the menopause, more women will be faced with the decision to consider hormone therapy, an option that may treat not only menopausal symptoms, but potentially, help maintain a healthy brain. Through the studies proposed here, we expect to not only advance our understanding of the neurobiology of hormones, but to establish the framework by which to expand the therapeutic window of opportunity for estrogens and progesterone.
|Nguyen, Trinh; Su, Chang; Singh, Meharvan (2018) Let-7i inhibition enhances progesterone-induced functional recovery in a mouse model of ischemia. Proc Natl Acad Sci U S A 115:E9668-E9677|
|Izurieta Munoz, Haydee; Gonzales, Eric B; Sumien, Nathalie (2018) Effects of creatine supplementation on nociception in young male and female mice. Pharmacol Rep 70:316-321|
|Montgomery, Christa L; Johnson, Heather M; Johnston, Thomas P et al. (2018) Mechanisms Underlying Early-Stage Changes in Visual Performance and Retina Function After Experimental Induction of Sustained Dyslipidemia. Neurochem Res 43:1500-1510|
|Grillo, Stephanie L; Montgomery, Christa L; Johnson, Heather M et al. (2018) Quantification of Changes in Visual Function During Disease Development in a Mouse Model of Pigmentary Glaucoma. J Glaucoma 27:828-841|
|Mock, J Thomas; Knight, Sherilynn G; Vann, Philip H et al. (2018) Gait Analyses in Mice: Effects of Age and Glutathione Deficiency. Aging Dis 9:634-646|
|Grillo, Michael A; Grillo, Stephanie L; Gerdes, Bryan C et al. (2018) Control of Neuronal Ryanodine Receptor-Mediated Calcium Signaling by Calsenilin. Mol Neurobiol :|
|Kaja, Simon; Payne, Andrew J; Naumchuk, Yuliya et al. (2017) Quantification of Lactate Dehydrogenase for Cell Viability Testing Using Cell Lines and Primary Cultured Astrocytes. Curr Protoc Toxicol 72:2.26.1-2.26.10|
|Gonzales, Eric B; Sumien, Nathalie (2017) Acidity and Acid-Sensing Ion Channels in the Normal and Alzheimer's Disease Brain. J Alzheimers Dis 57:1137-1144|
|Engler-Chiurazzi, E B; Brown, C M; Povroznik, J M et al. (2017) Estrogens as neuroprotectants: Estrogenic actions in the context of cognitive aging and brain injury. Prog Neurobiol 157:188-211|
|Engler-Chiurazzi, Elizabeth B; Covey, Douglas F; Simpkins, James W (2017) A novel mechanism of non-feminizing estrogens in neuroprotection. Exp Gerontol 94:99-102|
Showing the most recent 10 out of 132 publications